Actionable news
0
All posts from Actionable news
Actionable news in SRNE: Sorrento Therapeutics, Inc.,

Sorrento Therapeutics: Date

The following excerpt is from the company's SEC filing.

/s/ Henry Ji, Ph.D.

Director, Chief Executive Officer & President

(Principal Executive Officer)

/s/ Douglas Langston

Vice President of Finance

(Principal Financial and Accounting Officer)

EXHIBIT INDEX

10.1

Membership Interest Purchase Agreement by and among TNK Therapeutics, Inc., CARgenix Holdings LLC, the Members of CARgenix Holdings LLC, Jaymin Patel as the Members Representative and Sorrento Therapeutics, Inc. dated as of August 7, 2015**+.

10.2

Stock Purchase Agreement by and among TNK Therapeutics, Inc., BD L Products, Inc., the Stockholders of BDL Products, Inc., Richard Junghans, M.D., Ph.D. as the Stockholders Representative and Sorrento Therapeutics, Inc. dated as of August 7, 2015**+.

10.3

Binding Term Sheet with NanoVelcro Circulating Tumor Cell+

10.4

Exclusive License Agreement dated September 25, 2015 by and between LA Cell, Inc. and City of Hope*

31.1

Certification of Henry Ji, Ph.D., Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.+

31.2

Certification of Douglas Langston, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.+

32.1

Certification of Henry Ji, Ph.D., Principal Executive Officer, and Douglas Langston, Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended.+

101.INS

XBRL Instance Document+

101.SCH

XBRL Taxonomy Extension Schema Document+

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document+

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document+

101.LAB

XBRL Taxonomy Extension Label Linkbase Document+

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document+

Portions of this exhibit were omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to a request for confidential treatment.

Sorrento hereby undertakes to furnish supplementally a copy of any omitted schedule or exhibit to such agreement to the U.S. Securities and Exchange Commission upon request.

Previously filed.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Sorrento Therapeutics, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

James Velissaris just provided an update on activist position in Sorrento Therapeutics, Inc. - April 18, 2016
James Velissaris just provided an update on share ownership of Sorrento Therapeutics, Inc. - April 18, 2016
Sorrento Therapeutics, Inc.'s Executive VP and CFO just declared owning 4,000 shares of Sorrento Therapeutics, Inc. - April 8, 2016
Sorrento Therapeutics: Sorrento To Present At The Jefferies Immuno-Oncology Summit - April 6, 2016